---
schema_version: "secwatch.filing_event.v1"
accession: "0001680367-25-000044"
form_type: "8-K"
ticker: "STTK"
cik: "0001680367"
company_name: "Shattuck Labs, Inc."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T13:15:52.842836+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Shattuck Labs Q2 net loss narrows to $12.5M; IND submitted for SL-325 Phase 1, $103M private placement

## Summary
- Net loss of $12.5M ($0.24/sh) vs $21.6M ($0.42/sh) YoY; R&D costs fell to $8.7M from $19.2M.
- Cash $50.5M as of June 30; up to $103M from oversubscribed private placement led by OrbiMed to fund ops into 2029.
- Submitted IND for SL-325 (DR3 blocking antibody) in July 2025; clearance expected Q3 2025; first dosing in Phase 1 expected Q3 2025.
- Phase 1 trial in healthy volunteers to complete Q2 2026; funds expected to support operations into 2029.

## SEC filing metadata
- accession: 0001680367-25-000044
- form_type: 8-K
- ticker: STTK
- cik: 0001680367
- company_name: Shattuck Labs, Inc.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680367/000168036725000044/0001680367-25-000044-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680367/000168036725000044/sttk-20250814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001680367-25-000044
- JSON: https://secwatch.observer/filing/0001680367-25-000044.json
- Plain text: https://secwatch.observer/filing/0001680367-25-000044.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.